New Valeant Pharmaceuticals Intl Inc Board Sends Message As Firm Reinstates Earnings – ValueWalk Premium
Valeant 4 29

New Valeant Pharmaceuticals Intl Inc Board Sends Message As Firm Reinstates Earnings

The day after what was described as “the most brutal” Senate grilling of a corporate executives in memory, a beat-down involving Valeant Pharmaceuticals, the company restated earnings and materially re-shuffled the board of directors. While the restatement was material, it was the new board members focused on fraud and medical issues that points to the future. For investors, the question going forward is likely to have . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click chat.


X
Saved Articles

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

What’s missing today for many investors is real, straightforward advice.

Especially when it comes to Value Investing and Hedge Funds. 💵

That’s what makes ValueWalk Premium different. Some would say we’re “unusual.”

Our subscribers look forward to clear, easy-to-understand information they can act on.

Sign up for  today for only a few dollars a day and get a 3 day no obligation trial with a targeted 20% discount coupon code.

Cancel anytime during trial and you are never charged.

Limited time offer: For first 50 subscribers

0